If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through ...

Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of ...

If you want to know who really controls Amgen Inc. (NASDAQ:AMGN), then you'll have to look at the makeup of its share ...

Investing.com -- Bernstein cut its rating on Amgen Inc (NASDAQ:AMGN) to Market-Perform from Outperform, keeping its $335 price target, saying 2026 is likely to be a waiting year with limited catalysts ...

Goldman Sachs reiterates Buy rating and $403 price target for Amgen due to strong portfolio execution and 6 key growth ...

Johnson & Johnson reports Q4 earnings Jan 21 with 22% EPS growth expected. Stelara biosimilars and talc verdict weigh on ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Compass Therapeutics, Inc. is rated a Buy with strong cash position and strong data readout by the end of 1H 2026. Read more ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

In the closing of the recent trading day, Amgen (AMGN) stood at $320.71, denoting a -2.12% move from the preceding trading day.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...